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Abstract
Background: Non-Hodgkin lymphoma (NHL) is the fifth most common cancer in the U.S. and few causes have been
identified. Genetic association studies may help identify environmental risk factors and enhance our understanding of
disease mechanisms.
Methodology/Principal Findings: 768 coding and haplotype tagging SNPs in 146 genes were examined using Illumina
GoldenGate technology in a large population-based case-control study of NHL in the San Francisco Bay Area (1,292 cases
1,375 controls are included here). Statistical analyses were restricted to HIV- participants of white non-Hispanic origin. Genes
involved in steroidogenesis, immune function, cell signaling, sunlight exposure, xenobiotic metabolism/oxidative stress,
energy balance, and uptake and metabolism of cholesterol, folate and vitamin C were investigated. Sixteen SNPs in eight
pathways and nine haplotypes were associated with NHL after correction for multiple testing at the adjusted q,0.10 level.
Eight SNPs were tested in an independent case-control study of lymphoma in Germany (494 NHL cases and 494 matched
controls). Novel associations with common variants in estrogen receptor 1 (ESR1) and in the vitamin C receptor and matrix
metalloproteinase gene families were observed. Four ESR1 SNPs were associated with follicular lymphoma (FL) in the U.S.
study, with rs3020314 remaining associated with reduced risk of FL after multiple testing adjustments [odds ratio
(OR) = 0.42, 95% confidence interval (CI) = 0.23–0.77) and replication in the German study (OR= 0.24, 95% CI = 0.06–0.94).
Several SNPs and haplotypes in the matrix metalloproteinase-3 (MMP3) and MMP9 genes and in the vitamin C receptor
genes, solute carrier family 23 member 1 (SLC23A1) and SLC23A2, showed associations with NHL risk.
Conclusions/Significance: Our findings suggest a role for estrogen, vitamin C and matrix metalloproteinases in the
pathogenesis of NHL that will require further validation.
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Introduction
Non-Hodgkin lymphoma (NHL) is the most common hemato-
poietic cancer diagnosed in the U.S. Rates have increased steadily
over the last 30 years (http://www.leukemia-lymphoma.org).
Known risk factors include family history, exposure to infectious
agents and immunodeficiency associated with congenital condi-
tions and post-transplant therapy[1], though the causes for most
cases are unknown. Genetic and environmental factors that
influence the growth, survival and capacity of B-cells with pre-
neoplastic changes to undergo transformation[2] or that impact
the quality of tumor-specific immune responses may play integral
roles in lymphomagenesis. Approximately 80% of lymphomas are
of B-cell origin that arise during germinal center (GC) and post-
GC reactions as part of otherwise normal B-cell differentiation[3].
Diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL)
and small lymphocytic lymphoma/chronic lymphocytic leukemia
(SLL/CLL) are major lymphoma histologies that collectively
comprise ,75% of all NHL in industrialized countries. Whereas
DLBCL is a clinically aggressive disease for which incidence
increases with age, FL and SLL/CLL present a more indolent
clinical course. Molecular and phenotypic differences between
NHL histologies suggest they may have distinct etiologies, though
overlapping mechanisms are likely. The study of candidate single
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nucleotide polymorphisms (SNPs) may help to identify environ-
mental risk factors, further elucidate disease mechanisms and
discover novel targets for lymphoma treatment regimens. Thus, we
undertook a genetic study of 768 coding and haplotype tagging SNPs
in 146 genes in a population-based case-control study of NHL in the
San Francisco Bay Area (1,292 cases, 1,375 controls). The genes
investigated were primarily selected based on findings from our
earlier genetic studies[2,4–12] in pathways involved in steroidogen-
esis, immune function, cell signaling, sunlight exposure, xenobiotic
metabolism/oxidative stress, energy balance, as well as uptake and
metabolism of cholesterol, folate and vitamin C (Table 1). The most
compelling associations were tested in an independent population-
based case-control study of lymphoma based in Germany.
Results
Assessment of sample completion rates and SNP call
rates
Of the 768 SNPs genotyped in DNA of 2,667 study participants
(1,292 cases and 1,375 controls) from a large population-based case-
control study with more than 4,100 participants, eight samples were
excluded from further analyses due to missing SNP data (.10%)
yielding a sample completion rate of 99.7%. After restriction to white
non-Hispanics, 959 cases and 1,049 controls were included in the
final analysis. A total of 62 SNPs with call rates,90% were dropped
from the analysis yielding a SNP call rate of 91.9%. Additional
dropped SNPs included those with minor allele frequencies ,5%
(n= 29), X chromosome SNPs (n=7) and SNPs with Hardy-
Weinberg equilibrium p-values,0.01 (n=33) leaving a total of 637
SNPs for subsequent analyses. Two pairs of replicate DNAs on each
plate revealed genotype concordance rates of .99% within and
between plates. Genotype results concurred (.98.5%) with data
from the quality control Taqman genotyping of 10 SNPs on the
same study population. Single-marker allelic tests for all SNPs were
performed using x2 statistics. SNPs and haplotypes with the
strongest statistical associations (q-values#0.10) adjusted for multiple
comparisons using the false discovery rate (FDR) are shown in
Tables 2 and 3, respectively, while p-values for all SNPs are available
online (website). None of the associated SNPs violated HWE at the
p,0.05 level (Table 2).
Gene- and SNP-based analyses
SNPs in vitamin C receptor genes influence risk of NHL, FL
and SLL/CLL. SNP-specific analyses revealed that both SNPs
genotyped in the vitamin C receptor gene, solute carrier family 23
member 1 (SLC23A1), rs6596473 (IVS13+2515G.C) and
rs11950646 (IVS92110A.G), influenced risk of FL (p=
2.561022, q=8.461022, Table 2). Those homozygous variant for
either SNP had an 80% elevated risk of FL (Table S1). These SNPs
captured 75% of the haplotype structure in SLC23A1 (R2=0.99)
though no haplotype associations were found.
An intronic SLC23A2 SNP rs1776948 (IVS2217750G.A)
influenced NHL (p=4.761023, q=4.361022), FL (p=2.06
1022, q=8.461022) and SLL/CLL risk (p=1.161023, q=3.06
1022). In logistic regression analyses, the rs1776948 homozygous
variant 17750AA genotype was positively associated with disease
risk (Table S1). Notable associations were observed for two
additional intronic SLC23A2 SNPs, rs6133175 (IVS4+1767A.G)
and rs1715364 (IVS3+14205T.C) (q,0.05), where the homozy-
gous variant genotypes yielded two-fold increased risks for SLL/
CLL (Table S1). TFSEARCH (http://www.cbrc.jp/research/db/
TFSEARCH.html) predicted that the SLC23A2 rs1715364 wild
type T allele creates binding sites for the GATA-1 and GATA-2
enhancer proteins that may increase SLC23A2 expression. LD
structure for SLC23A2 is shown in Figure S1. Given the size of this
gene (,158 Kb), the seven SLC23A2 tag SNPs genotyped only
captured 35% of its haplotype structure at the R2= 0.94 level.
Though gene coverage was low, haplotype associations were found
with NHL, DLBCL and SLL/CLL risk (Table 3). A two-SNP AA
haplotype (rs1776948 and rs6139587) was positively associated
with NHL and SLL/CLL and an AAC haplotype derived from
minor alleles for rs1715385 and rs1715364 and the wildtype allele
for rs6133175 was associated with increased risk of NHL and
DLBCL. However, p-values derived from SLC23A2 haplotype
associations predicted no greater risks beyond those observed for
the individual SNPs.
Matrix metalloproteinase (MMP)3 and MMP9 SNPs
influence FL and SLL/CLL risk. A significant association
was found between FL and a non-synonymous MMP3 45K.E
SNP, (rs679620, A.G) (p=3.761024; q=1.261022; Table 2).
Logistic regression analyses revealed that the MMP3 45EE
Table 1. Pathways/gene functional groups of analyzed candidate genes in the San Francisco Bay Area NHL study.
Pathway/Gene Function
Steroidogenesis (n = 22) CYP11B1, CYP11B2, CYP21A2, NR3C1, AR, CYP17A1, CYP19A1, COMT, ESR1, ESR2, HSD17B1, HSD17B2, HSD3B1,
HSD3B2, NCOA3, PGR, PRL, PRLR, SERPINA6, SHBG, SRD5A1, SRD5A1
Immunity (n = 22) IL10, 1L4, IL4R, CTLA4, FCER2, FCGR2A, FCGR3A, VCAM1, ICAM1, C4A, HLA-DQB1, NFKB1, NFKBIA, NFKBIB, TNFRSF5,
TNFSF8, CCL2, CCL5, CCL8, CCR3, CX3CR1, CXCR4
Cell signaling/apoptosis (19) BAD, BAX, BAK1, BCL2, BCL2L1, BCL6, BIK, FLT1, ITGB2, NFKB1, NFKB1A, MMP1, MMP2, MMP3, MMP9, VEGF, SOCS3,
STAT3, STAT6
Sunlight/vitamin D (n = 12) CDK4, CDKN2A, CDKN2B, ERCC2, MC1R, MITF, OCA2, TYR, VDR, VDRIP, XRCC1, POMC
Xenobiotic metabolism/oxidative stress (n = 14) AHR, CYP1A1, CYP2E1, EPHX1, EPHX2, NAT1, NAT2, PTGS1, PTGS2, GPX4, MPO, SOD1, SOD2, NQO1
Energy balance (n = 38) ADRB2, ADRB3, APOA2, APOA4, APOB, APOE, ESR1, GH1, GHR, GHRL, HP, IGFI, IGFIR, IGF2, IGF2R, IGFBP1, IGFBP3, LEP,
LEPR, LTA, NPY, POMC, PARP1, PPARD, PPARG, PTPN1, SIRT1, TNFRSF1B, CYP11B1, CYP21A2, NR3C1, DRD2, DRD3,
DRD5, SLC6A3, COMT, PRL, PRLR
Cholesterol synthesis/metabolism (n = 19) ACBD3, ADAM17, BZRP, CETP, FDFT1, HMGCS1, HMGCS2, LIPC, LPL, NPC1, NPC2, NR1H2, NR1H3, STAR, STARD3NL,
TIMP1, TIMP3, TNFSF8, TPRT
Diet
Folate metabolism (n = 7) ADH5, CBS, DHFR, MTHFR, MTR, SHMT2, TYMS
Vitamin C uptake (n = 2) SLC23A1, SLC23A2
doi:10.1371/journal.pone.0002816.t001
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allelotype was associated with a 70% increased risk for FL (Table
S2). RESCUE ESE[13] predicted that the MMP3 45E variant
introduces two exonic splicing enhancer motifs that could augment
exon 2 splicing and increase MMP3 expression. This SNP,
together with rs615098, located in the MMP3 promoter region,
captured 44% of all common HapMap SNPs in the region at a
mean R2 of 0.99.
Two non-synonymous SNPs in MMP9 (279Q.R, rs17576;
668R.Q, rs2274756) influenced SLL/CLL status (p=7.061023,
q=9.561022; p=1.061022, q=9.561022, respectively; Tables 2,
S2). For the 668Q allele, ESEfinder identified an extra SF2/ASF
motif that could enhance exon 2 splicing and increase MMP9
expression. Interestingly, the 668R.Q SNP was in complete LD
with a MMP9 promoter SNP, rs3918241 (D’ = 1.0), where the
variant A allele was positively associated with SLL/CLL
(p=1.061022; q=9.561022; Tables 2, Table S2). TFSEARCH
predicts that the rs3918241 A allele creates extra GATA-1, Oct-1,
GATA-2 and GATA-X binding motifs, suggesting increased
promoter activity for the variant A allele. MMP9 variation was
organized into a single LD block spanning the gene and its
promoter region (Figure S2). Thus, the five MMP9 SNPs
genotyped captured 78% of all common variation for this region
at a mean R2 of 0.98.
Sex hormone SNPs influence risk of lymphoma. The
regression analyses (see methods) revealed an association between
the cytochrome P450 (CYP)19A1 gene and risk for FL
(p=6.361023). Eight CYP19A1 SNPs influenced risk for FL and
SLL/CLL, though considering a q,0.10, only rs1870049
(IVS1+5469T.C) remained associated with disease status
(p=6.061024; q=4.961022, Table 2). In logistic regression
analyses, the rs1870049 homozygous variant CC genotype was
associated with a three-fold increased risk for FL (Table S3). Four
additional CYP19A1 SNPs, rs10046 (39UTR, 1678T.C), rs2289105
(IVS7279T.C), rs2899472 (IVS421334C.A), rs9944225
(IVS3+7029C.A) and rs4774584 (IVS1226860G.A) influenced
SLL/CLL risk (Table S2) and rs2008691 (IVS1213201A.G) was
positively associated with the group of ‘‘other’’ lymphoma subtypes
(Table S3). CYP19A1 SNP associations did not differ by sex (data not
shown). We also found a CYP19A1 five-SNP high-risk FL haplotype
(p=6.561024, q=2.961022, Table 3) that included the rs1870049
variant C allele. A haplotype with the rs1870049 T allele did not
influence FL risk, suggesting that the C allele was driving the
haplotype association. Analysis of LD structure throughout the
region revealed that the haplotype lies within an 18 kb region of
relatively high LD spanning the 59 UTR of CYP19A1 (Figure S3).
The 14 genotyped SNPs, uniformly distributed throughout the gene,
captured 66% of CYP19A1 common genetic variation at a mean R2
of 0.96.
An intronic SNP, rs3020314 (IVS4+5029T.C), in the estrogen
receptor alpha (ESR1) gene was associated with risk of FL
(p=1.661023, q=7.061022, Table 2). Logistic regression analyses
revealed that the rs3020314 homozygous variant IVS4+5029CC
genotype was associated with a 58% reduced risk of FL (Table S4).
This SNP was in almost complete LD (D’.0.9,R2.0.90) with three
other SNPs that form part of a 14 kb haplotype block of 9 common
SNPs located between exons 4 and 5. Homozygous variant
genotypes for three additional ESR1 SNPs, rs488133 (promo-
ter23604C.T), rs532010 (IVS1+1419T.C) and rs827423
(IVS127534T.C) also were associated with FL (Table S4). These
three SNPs formed part of a major haplotype block that extended
43 kb from the 59 upstream region to exon 2, which includes another
32 HapMap genotyped SNPs. LD structure analysis (Figure S4)
revealed that some of the 11 ESR1 SNPs genotyped in this study are
located at the borderlines of blocks close to recombination hotspots.
These SNPs, at a density of one every,28 Kb, captured only 25%
of the common variation in ESR1.
Other genetic associations with NHL. In the cholesterol
genes, considering q-values,0.10, we found an association between
NHL and the nuclear receptor subfamily 1, group H, member 2
(NR1H2) gene (p=1.861023, q=3.561022) in the regression
analysis. NR1H2 is involved in cholesterol homeostasis and bile
acid metabolism. For FL, we found gene and SNP (20T.C)
associations with farnesyl-diphosphate farnesyltransferase 1(FDFT1),
which plays a key role in cholesterol biosynthesis (gene,
p=4.161023; q=7.861022; rs1047643, p=8.461024, q=5.26
1022, Table 2). According to ESEfinder, the rs1047643 C allele
introduces an extra SRp55 motif that may influence pre-mRNA
processing or splicing efficiency. This SNP was included in a FL
high-risk FDFT1 haplotype (p=1.661023, q=6.461022, Table 3),
though the p-value was no more significant for the haplotype than for
the rs1047643 SNP association. No other FDFT1 SNP associations
were observed. The four FDFT1 SNPs genotyped captured 52% of
common variation in FDFT1 (R2=0.92).
In cell signaling genes, we found an association with NHL and
the BCL6 gene (p=3.461023, q=7.861022), though no single
SNP significantly influenced risk. We also found that an intronic
Table 3. Associated haplotypes with corrected p-values (q),0.10 for the San Francisco Bay Area NHL case-control study.
Subtype Pathway Gene rs id Haplotype p-value q-value OR (95% CI)
All NHL Vitamin C SLC23A2 rs1776948, rs6139587 10 (AA) 2.061023 4.661022 1.2 (1.02–1.4)
rs1776948, rs6139587 01 (GT) 2.061023 4.661022 0.82 (.69–.97)
rs1715385, rs6133175, rs1715364 101 (AAC) 8.061024 4.661022 1.4 (1.07–1.8)
FL Cholesterol FDFT1 rs2645444, rs1047643, rs3258, rs1296028 0100 [28] 1.661023 6.461022 1.7 (1.2–2.3)
Steroidogenesis CYP19A1 rs1004982, rs2470146, rs2470144, rs1870049,
rs752760
10011 (GTGCT) 6.561024 2.961022 1.7 (1.3–2.4)
DLBCL Vitamin C SLC23A2 rs1715385, rs6133175, rs1715364 101 (AAC) 7.361023 4.461022 1.6 (1.1–2.4)
SLL/CLL Vitamin C SLC23A2 rs1776948, rs6139587 10 (AA) 1.861023 1.161022 1.7 (1.2–2.3)
Cell signaling/apoptosis BIK rs747745, rs9620115, rs5751435, rs11574528,
rs13815
01011 (AGCTC) 8.061024 3.761022 2.1 (1.4–3.4)
Xenobiotic/oxdative stress EPHX2 rs4149244, rs747276 11(TC) 1.061023 2.061022 2.1 (1.3–3.3)
NHL: non-Hodgkin lymphoma; FL: follicular lymphoma; DLBCL: diffuse large B-cell lymphoma; SLL: small lymphocytic lymphoma; CLL: chronic lymphocytic leukemia.
doi:10.1371/journal.pone.0002816.t003
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SNP rs760462 (IVS3+2100G.A) in integrin beta 2 (ITGB2)
influenced FL status (p=9.761024, q=7.261022, Table 2), where
the 2100AA genotype increased FL risk three-fold (Table 3). No
other associations were found with ITGB2, however the six SNPs
genotyped captured only 21% of the variation in the ITGB2 gene
(R2= 0.99).
For SLL/CLL, the variant allele for rs4149244 (IVS9+1573C.T)
in the epoxide hydrolase 2 (EPHX2) gene was positively associated
with disease risk (p=1.261023, q=4.561022, Table 2).
TFSEARCH predicts that the T allele introduces a CdxA binding
site, suggesting that this allele may act to enhance EPHX2 gene
expression. Gene coverage for the four EPHX2 SNPs genotyped was
58% (R2= 0.96). The rs414924 T allele also comprised a two-SNP
haplotype that was associated with FL risk (p=1.061023,
q=2.061022, Table 3), though again the haplotype was no more
likely to contribute to risk than the rs4149244 SNP. Finally, a five-
SNP haplotype in the apoptosis/signaling gene, BCL2-interacting
killer (BIK) was associated with an increased risk for SLL/CLL
(Table 2), though no SNP associations were detected. Gene coverage
for the seven BIK SNPs genotyped was 75% (R2=0.95).
Validation Study
We next tested for association of significant findings in an
independent case-control study of lymphoma in Germany that
comprised 494 NHL cases and 494 age and sex-matched controls.
An additional 111 Hodgkin lymphoma cases and 111 matched
controls also were analyzed. The criterion used for selection of
SNPs in Table 2 was that there was .1 associated signal in a
particular pathway and in more than one gene. When SNPs were
closely linked (R2.0.8), only one SNP was chosen for validation.
Eight SNPs were genotyped in the SLC23A1 (rs6596473,
rs11950646) and SLC23A2 (rs1715364), MMP3 (rs679620),
MMP9 (rs3918241), CYP19A1 (rs1870049, 2899472) and ESR1
(3020314) genes (Table 4).
The SLC23A1 rs6596473 and rs11950646 SNPs associated with
increased FL risk in the U.S. study (OR=1.8, 95% CI= 1.2–2.9,
p=8.861023 and OR=1.8, 95% CI= 1.2–2.8, p=8.361023,
respectively), did not influence risk of FL in the German study.
However, in the German study, risk estimates were elevated for
CLL (OR=3.4, 95% CI=0.91–13, p=7.061022; OR=2.6, 95%
CI= 0.85–7.9, p=9.061022, respectively) and ORs were reduced
for DLBCL (OR=0.39, 95% CI= 0.13–1.1, p=8.061022 and
OR=0.44, 95% CI= .17–1.1, p=9.061022, respectively). Con-
sistent with the U.S. study, the SLC23A2 rs1715364 CC genotype
was associated with an elevated OR for SLL/CLL (U.S.:
OR=1.9, 95% CI= 1.2–3.1, p=5.561023; Germany:
OR=1.8, 95% CI=0.77–4.1, p=1.861021), though the confi-
dence interval included one.
For MMP3 rs679620 where the US study found an increased
risk for FL associated with the homozygous variant genotype
(OR=1.7, 95% CI= 1.1–2.6, p=1.961022), the German study
found no associations with NHL. However, the homozygous
variant genotype was associated with an increased risk for HL
(OR=2.3, 95% CI= 0.99–5.4, p=5.461022). Consistent with
findings in the U.S. study, homozygosity for the MMP9 rs3918241
variant resulted in an elevated OR for NHL approaching
significance (US: OR=1.7, 95% CI= 0.95–3.0, p=7.461022;
Germany: OR=2.5, 95% CI= 0.80–8.1; p=1.061021), however,
there was no increased risk of CLL with the variant allele as found
in the U.S. study.
In the German study, CYP19A1 rs1870049 failed Pyrosequen-
cing genotyping and no differences in rs2899472 allele frequencies
were observed between cases and controls. The most robust
findings were for ESR1 rs3020314 where, as in the US study,
heterozygous and homozygous variant genotypes were inversely
related with FL risk in the German study (U.S.: heterozygous
OR=0.64, 95% CI= 0.46–0.88, p=6.261023; homozygous
variant OR=0.42, 95% CI= 0.23–0.77, p=5.161023; Germany:
heterozygous OR=0.47, 95% CI= 0.22–1.0, p=5.761022;
homozygous variant OR=0.24, 95% CI= 0.06–.094,
p=4.061022). The ESR1 rs3020314 variant allele also was
associated with HL in the German study (OR=0.61, 95%
CI= 0.35–1.1, p=7.761022).
Discussion
Here, we report that SNPs in the vitamin C receptor and matrix
metalloproteinase gene families and in genes involved in estrogen
responsiveness may be risk alleles for NHL. Our main strategy was
to use a hypothesis-driven approach to further examine genetic
findings based on our earlier studies by genotyping SNPs in related
pathways or in genes that share common biological functions to
those previously associated with NHL [2,4–12]. We selected
potential functionally relevant SNPs including non-synonymous
coding SNPs, and 1–15 haplotype tagging SNPs were genotyped
based on known patterns of LD using data available from the
HapMap CEU population. These tag SNPs captured an average
39% of all common SNPs (R2.0.8) in the studied genes and their
flanking regions. We note that the low coverage in some genes
may have precluded us from detecting additional NHL risk alleles.
Analyses were restricted to white non-Hispanics with ancestry data
to reduce population stratification. In 959 cases and 1,049 controls,
we identified 14 unique SNPs in eight pathways and seven
haplotypes associated with NHL after correction for multiple testing
at the adjusted q,0.10 (estimated FDR) level, and seven SNPs and
eight haplotypes remained significantly associated with lymphoma
risk at the q,0.05 level. We utilized in silico algorithms to predict
likely functional effects for associated SNPs. Next, in an independent
case-control study of lymphoma, we performed a small replication
analysis of associated SNPs that were chosen based on the criteria
that multiple SNP-NHL associations were observed in the same gene
or gene family. In doing so, we found a strong inverse association
between FL and an intronic SNP in ESR1 in both study populations.
Other associations were observed between risk of lymphoma
subtypes and SLC23A1, SLC23A2, and MMP9 SNPs. Although
several of these associations occurred within different NHL subtypes
across the two study populations, the overall consistency of
associations with specific genes provides some support that these
genes might be associated with NHL risk. Replication in additional
populations and investigation of molecular similarities and differ-
ences of NHL subtypes such as through tumor microarray studies
will be needed to clarify these findings.
Vitamin C and risk of NHL
The associations we identified between NHL and SNPs in the
vitamin C receptor genes may provide indirect evidence to support
epidemiological data showing inverse associations between NHL
risk and intakes of fruits and vegetables, which are primary sources
of dietary vitamin C [14,15]. Here, we observed that homozygous
variant genotypes for two closely linked intronic SLC23A1 SNPs,
rs6596473 and rs11950646, were positively associated with FL in
the U.S. study. However, in the German study, these genotypes
were inversely and positively associated with DLBCL and SLL/
CLL risk, respectively, suggesting that further study will be needed
to determine the relevance, if any, of these findings. In the U.S.
analysis of seven SLC23A2 SNPs, we found that variant alleles for
rs6133175 and rs1715364 increased SLL/CLL risk and rs1776948
for FL and SLL/CLL. In genotyping SLC23A2 rs1715364 in the
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Table 4. Odds ratios (OR) and 95% confidence intervals (CI) for associated SNPs in the SLC23A1, SLC23A2, MMP3, MMP9, CYP19A1
and ESR1 genes in the San Francisco Bay Area NHL and German studies.
SNP and
Genotype All NHL OR(95% CI)
DLBCL
n(%) OR(95% CI) FL n(%) OR(95% CI) SLL n(%) OR(95% CI)
Controls
(US=1049,
GER=494) %
SLC23A1 (rs6596473)
US GG 422 (44) 1.0 123 (46) 1.0 82 (41) 1.0 74 (49) 1.0 48
CG 421 (44) 1.1 (.93–1.4) 122 (45) 1.1 (.85–1.5) 85 (43) 1.2 (.86–1.7) 58 (38) .86 (.59–1.2) 42
CC 114 (12) 1.2 (.91–1.6) 25 (9.0) .91 (.57–1.5) 33 (17) 1.8 (1.2–2.9) 19 (13) 1.2 (.67–2.0) 11
CG/CC 535 (56) 1.1 (.96–1.4) 147 (54) 1.1 (.83–1.4) 118 (59) 1.3 (.97–1.8) 77 (51) 0.92 (.65–1.3) 52
P for trend 0.11 0.90 0.01 1.0
Germany GG 215 (46) 1.0 66 (46) 1.0 44 (56) 1.0 41 (43) 1.0 51
CG 208 (45) 1.2 (.93–1.6) 71 (49) 1.0 (.60–1.7) 29 (37) 1.1 (.57–2.0) 41 (43) 1.0 (.58–1.8) 40
CC 42 (9) 1.1 (.67–1.7) 8 (5) .39 (.13–1.1) 6 (8) 1.2 (.37–4.0) 13 (14) 3.4 (.91–13) 9
CG/CC 250 (54) 1.2 (.93–1.6) 79 (54) .89 (.55–1.4) 35 (44) 1.1 (.61–2.0) 54 (57) 1.2 (.70–2.1) 49
P for trend 0.28 0.24 0.73 0.19
SLC23A1 (rs11950646)
US AA 380 (40) 1.0 112 (42) 1.0 75 (38) 1.0 65 (43) 1.0 43
AG 436 (46) 1.1 (.92–1.3) 125 (47) 1.1 (.81–1.4) 84 (42) 1.1 (.79–1.6) 63 (42) .91 (.62–1.3) 44
GG 133 (14) 1.2 (.90–1.6) 31 (12) .94 (.60–1.5) 39 (20) 1.8 (1.2–2.8) 22 (15) 1.2 (.68–1.9) 13
AG/GG 569 (60) 1.1 (.94–1.3) 156 (58) 1.1 (.80–1.4) 123 (62) 1.3 (.92–1.7) 85 (57) 0.96 (.68–1.4) 57
P for trend 0.17 0.98 0.02 0.84
Germany AA 198 (42) 1.0 63 (43) 1.0 37 (47) 1.0 36 (37) 1.0 46
AG 225 (48) 1.2 (.91–1.6) 75 (51) .90 (.54–1.5) 34 (44) 1.3 (.69–2.3) 46 (48) 1.3 (.74–2.4) 44
GG 44 (10) 1.0 (.64–1.6) 9 (6) .44 (.17–1.1) 7 (9) 1.9 (.55–6.7) 14 (15) 2.6 (.85–7.9) 10
AG/GG 269 (58) 1.2 (.90–1.5) 84 (57) .81 (.49–1.3) 41 (53) 1.4 (.76–2.4) 60 (63 ) 1.5 (.82–2.6) 54
P for trend 0.47 0.15 0.24 0.09
SLC23A2 (rs1715364)
US TT 275 (29) 1.0 77 (28) 1.0 63 (32) 1.0 37 (25) 1.0 30
CT 473 (49) 1.0 (.84–1.3) 145 (54) 1.1 (.83–1.5) 96 (48) .91 (.64–1.3) 68 (45) 1.1 (.74–1.7) 51
CC 210 (22) 1.2 (.95–1.6) 49 (18) 1.0 (.69–1.5) 41 (21) 1.1 (.70–1.7) 46 (30) 1.9 (1.2–3.1) 19
CT/TT 680 (71) 1.1 (.89–1.3) 194 (72) 1.1 (.82–1.5) 137 (69) 0.95 (.69–1.3) 114 (76) 1.4 (.92–2.0) 70
P for trend 0.14 .78 0.86 6.461023
Germany TT 126 (28) 1.0 38 (27) 1.0 25 (32) 1.0 23 (24) 1.0 29
CT 238 (52) 1.2 (.85–1.6) 72 (51) .76 (.41–1.4) 41 (53) 1.2 (.59–2.4) 49 (52) 1.7 (.81–3.4) 46
CC 92 (20) .86 (.60–1.2) 30 (21) .71 (.36–1.4) 11 (14) .58 (.25–1.4) 23 (24) 1.8 (.77–4.1) 25
TC/CC 330 (72) 1.0 (.78–1.4) 102 (73) .74 (.42–1.3) 52 (68) .95 (.50–1.8) 72 (76) 1.7 (.85–3.4) 71
P for trend 0.41 0.34 0.29 0.18
MMP3 (rs679620)
US AA 252 (26) 1.0 72 (27) 1.0 38 (19) 1.0 47 (32) 1.0 26
AG 442 (46) .93 (.75–1.2) 132 (49) .97 (.70–1.3) 98 (49) 1.4 (.91–2.0) 64 (43) .72 (.48–1.1) 49
GG 260 (27) 1.0 (.82–1.3) 66 (24) 0.92 (.63–1.3) 64 (32) 1.7 (1.1–2.6) 38 (26) .82 (.52–1.3) 26
AG/GG 702 (74) 0.97 (.79–1.2) 198 (73) 0.95 (.70–1.3) 162 (81) 1.5 (1.0–2.2) 102 (68) 0.76 (.52–1.1) 74
P for trend 0.75 0.67 0.02 0.38
Germany AA 121 (26) 1.0 42 (30) 1.0 24 (30) 1.0 22 (23) 1.0 28
AG 235 (51) 1.1 (.85–1.6) 75 (53) 1.3 (.73–2.2) 38 (48) .95 (.47–1.9) 50 (53) 1.2 (.60–2.4) 48
GG 104 (23) 1.00 (.70–1.4) 25 (18) .63 (.33–1.2) 17 (22) .70 (.31–1.6) 23 (24) 1.3 (.60–2.9) 24
AG/GG 339 (74) 1.1 (.83–1.5) 100 (70) 1.0 (.60–1.7) 55 (70) .85 (.45–1.6) 73 (77) 1.3 (.65–2.4) 72
P for trend 0.93 0.20 0.42 0.48
MMP9 (rs3918241)
US TT 656 (69) 1.0 199 (74) 1.0 135 (68) 1.0 95 (63) 1.0 73
AT 271 (28) 1.2 (.99–1.5) 64 (24) 0.94 (.69–1.3) 62 (31) 1.3 (.95–1.9) 50 (33) 1.6 (1.1–2.3) 25
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German study, the variant CC genotype was associated with an
elevated OR for CLL, consistent with findings from the U.S.
study. The haplotype analyses supported the genotype results but
added nothing further to the individual SNP associations.
SLC23A1 and 2 encode two vitamin C transport proteins,
SVCT1 and 2, respectively[16] that exhibit non-redundant
functions[17]. The lethality of slc23a1 and slc23a2 mouse
knockouts highlights the relevance of these proteins in maintaining
vitamin C homeostasis [17,18]. In humans, SVCT1 is expressed in
kidney, intestinal, hepatic and placental tissues and is critical for
vitamin C absorption and reabsorption, whereas SVCT2 is
expressed in most tissues and is essential for vitamin C
bioaccumulation[19]. Thus, the influence of SLC23A1 and
SLC23A2 genetic variation on NHL risk suggests that both vitamin
C uptake and storage may be involved in the pathogenesis of
lymphoma. In silico models suggest that the SLC23A2 rs1715364 T
allele may augment SLC23A2 expression and increase vitamin C
bioavailability, which will need to be tested in functional studies.
By extension, if the variant C allele results in lower SLC23A2
expression, then the increased NHL risk associated with the
variant C allele might suggest that reduced vitamin C bioavail-
ability increases lymphoma risk.
As with the majority of SNPs investigated in this study, SLC23A1
and SLC23A2 SNPs were chosen as tag SNPs to gain gene coverage
to capture potential causal variants. Though SLC23A1 and SLC23A2
have extensive sequence homology, SLC23A2 is a 10-fold larger gene
with a much more complex locus architecture (Figure S1). Whereas,
two SLC23A1 tag SNPs captured 75% of its haplotype structure,
seven SLC23A2 tag SNPs captured only 35% of its haplotype
structure at an R2.0.94, warranting the need for additional fine
mapping of the SLC23A2 gene.
In pooled analyses of two NHL case-control studies, we
previously reported that SNPs that impair anti-oxidant capacity
may influence lymphomagenesis[5]. Vitamin C is an essential
enzyme cofactor in reactions catalyzed by several metal-dependent
oxygenases[20]. It also functions as a scavenger of reactive oxygen
species[21] and, thus, may play an important role in preventing
oxidative stress induced DNA damage by quenching free radical
Table 4. cont.
SNP and
Genotype All NHL OR(95% CI)
DLBCL
n(%) OR(95% CI) FL n(%) OR(95% CI) SLL n(%) OR(95% CI)
Controls
(US=1049,
GER=494) %
AA 30 (3.1) 1.7 (.95–3.0) 7 (2.6) 1.3 (.54–3.1) 4 (2.0) 1.1 (.36–3.1) 6 (4.0) 2.4 (.93–6.1) 2
AT/AA 301 (31) 1.2 (1.0–1.5) 71 (26) 0.97 (.71–1.3) 66 (33) 1.3 (.95–1.8) 56 (37) 1.6 (1.1–2.3) 27
P for trend 0.01 0.99 0.15 4.861023
Germany TT 354 (76) 1.0 114 (78) 1.0 59 (75) 1.0 72 (76) 1.0 78
AT 102 (22) 1.1 (.80–1.5) 28 (19) .82 (.46–1.5) 19 (24) 1.2 (.54–2.5) 22 (23) 1.4 (.68–2.86) 21
AA 10 (2) 2.5 (.80–8.1) 5 (3) 2.4 (.47–12.56) 1 (1) - 1 (1) 1.2 (.07–19.49) 1
AT/AA 112 (24) 1.1 (.84–1.5) 33 (22) .92 (.54–1.6) 20 (25) 1.3 (.59–2.7) 23 (24) 1.4 (.68–2.8) 22
P for trend 0.24 0.91 0.47 0.40
CYP19A1 (rs2899472)
US CC 498 (52) 1.0 146 (54) 1.0 100 (50) 1.0 66 (44) 1.0 57
AC 390 (41) 1.2 (1.0–1.5) 112 (41) 1.2 (.92–1.6) 80 (40) 1.3(.92–1.8) 67 (44) 1.6 (1.1–2.3) 36
AA 71 (7.4) 1.1 (.81–1.6) 13 (4.8) .72 (.39–1.3) 21 (10) 1.7 (1.0–2.9) 18 (12) 2.2 (1.3–4.0) 7
AC/AA 461 (48) 1.2 (1.0–1.5) 125 (46) 1.1 (.87–1.5) 101 (50) 1.3 (.99–1.8) 85 (56) 1.7 (1.2–2.4) 43
P for trend 0.06 0.84 0.03 1.261023
Germany CC 276 (59) 1.0 88 (60) 1.0 49 (62) 1.0 55 (58) 1.0 53
AC 157 (34) .75 (.57–1.00) 49 (34) .79 (.48–1.3) 23 (29) .60 (.29–1.2) 36 (38) .63 (.34–1.2) 41
AA 32 (7) 1.0 (.60–1.8) 9 (6) .78 (.32–1.9) 7 (9) 1.5 (.36–6.4) 4 (4) 1.1 (.24–5.1) 6
AC/CC 189 (41) .79 (.60–1.0) 58 (40) .79 (.50–1.2) 30 (38) .67 (.34–1.3) 40 (42) .67 (.37–1.2) 47
P for trend 0.23 0.33 0.58 0.30
ESR1 (rs3020314)
US TT 435 (46) 1.0 122 (45) 1.0 112 (56) 1.0 62 (41) 1.0 43
TC 423 (44) 0.93 (.78–1.1) 115 (43) .90 (.68–1.2) 76 (38) .64 (.46–.88) 68 (45) 1.1 (.74–1.5) 45
CC 98 (10) 0.83 (.62–1.1) 33 (12) .99 (.64–1.5) 13 (6) .42 (.23–.77) 21 (14) 1.3 (.75–2.2) 12
TC/CC 521 (55) 0.91 (.76–1.1) 148 (55) .92 (.70–1.2) 89 (44) .59 (.44–.81) 89 (59) 1.1 (.79–1.6) 57
P for trend 0.21 0.72 4.061024 0.39
Germany TT 221 (48) 1.0 67 (46) 1.0 43 (56) 1.0 49 (51) 1.0 48
TC 205 (44) 1.0 (.78–1.4) 71 (48) 1.1 (.67–1.8) 30 (39) .47 (.22–1.0) 37 (39) .91 (.50–1.7) 44
CC 38 (8) 1.0 (.62–1.7) 9 (6) 1.0 (.38–2.8) 4 (5) .24 (.06–.94) 10 (10) .95 (.36–2.5) 8
TC/CC 243 (52) 1.0 (.79–1.3) 80 (54) 1.1 (.68–1.8) 34 (44) .42 (.20–.87) 47 (49) .92 (.51–1.6) 52
P for trend 0.87 0.77 0.01 0.82
1ORs generated by conditional logistic regression.
doi:10.1371/journal.pone.0002816.t004
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formation. Other possible modes of action may involve vitamin
C’s anti-tumorigenic role in supporting proper collagen formation
and matrix stabilization[22]. Further, in an in vitro study of T-cell
leukemia, vitamin C abrogated cell proliferation and induced
apoptosis through p53, p21, Bcl-2 and Bax modulation[23].
Additional studies will be needed to clarify the role of vitamin C in
the pathogenesis of NHL.
MMP SNPs influence NHL, FL and SLL/CLL risk
Extracellular matrix degradation is involved in many normal
physiological processes including development, growth and tissue
repair. However, high MMP-3 and -9 proteolytic enzyme levels
also may support tumor cell proliferation, angiogenesis, invasion
and metastasis[24,25] by degrading type IV collagen, penetrating
the basement membrane and invading surrounding tissues[26].
High MMP expression is found in lymphoid cells and malignantly
transformed cells[27]. Recent studies highlight the relevance of
MMPs and angiogenesis in lympho-hematological malignancies
such as B-cell lymphoma, multiple myeloma, CLL and acute
lymphocytic and myeloid leukemias[28]. While the MMP family
has been related to cancer invasion and metastases, our study
suggests that variation in MMP genes also plays a role in
lymphomagenesis. Here we found that homozygosity for a non-
synonymous MMP3 45K.E SNP, rs679620, was associated with
increased risk of FL in the U.S. study, and for HL in the German
study. It is biologically feasible that the MMP3 45EE allelotype
may influence lymphomagenesis since it is predicted by RESCUE
ESE to enhance exon 2 splicing, which may increase MMP3
expression. In the U.S. study, increased FL and SLL/CLL risk
also was found in those possessing variant alleles for an MMP9
promoter SNP, rs3918241, and two non-synonymous MMP9
SNPs, rs17576 (279Q.R) and rs2274756 (668R.Q). According
to ESEfinder, the rs3918241 variant A allele may enhance MMP9
promoter activity and the rs2274756 variant 668Q allelotype
creates an extra binding motif that may enhance exon 2 splicing.
Thus, the rs3918241 and rs2274756 risk alleles for SLL/CLL are
predicted to increase MMP9 expression. We tested the association
of rs3918241 in the German study and found an elevated though
non-significant increase in NHL risk, consistent with the U.S.
study, though there was no evidence of an association with FL and
CLL as in the U.S. study. The 4% frequency of the homozygous
variant genotype may have precluded us from observing these
associations, which will require the study of this SNP in larger
populations. Since rs3918241 and rs2274756 are in complete LD,
additional studies also will be needed to discern which, if any, of
these functionally relevant SNPs may be causally related to NHL.
In earlier studies, we found associations with NHL and SNPs in
energy regulation genes such as leptin (LEP), leptin receptor (LEPR)
and ghrelin (GHRL)[9,11,12]. We hypothesized that leptin may
promote lymphomagenesis through mitogenic and anti-apoptotic
effects on B-cell populations through LEPR-mediated upregulation
of BCL-2, MMPs, and tissue inhibitors of metalloproteinases. The
present study lends further credence to the role of MMPs in
lymphomagenesis. Interestingly, our study found multiple genetic
associations with LEPR, GHRL and SNPs in other energy regulatory
genes, though the adjusted q-values were .0.10. In light of these
findings, we plan to further study the relationship between energy
regulation and MMP SNPs in lymphomagenesis.
ESR1 and CYP19A1 gene variants in association with
lymphoma risk
Previously, we reported a CYP17A1234T.C high-risk genotype
for DLBCL in two independent case-control studies of NHL[7,10].
CYP17A1 produces key enzymes that catalyze the synthesis of estrone
and dehydroepiandrosterone, the precursors for estrogen and
testosterone. These findings prompted us to explore SNPs in
additional genes involved in steroidogenesis and in estrogen and
testosterone uptake and metabolism. Unfortunately, in the present
study, we were unable to obtain genotype calls for CY-
P17A1234T.C due to poor genotype clustering. Additionally, we
had insufficient SNP coverage across ESR1 since some tags were
located in the lower LD regions (Figure S4). Nonetheless, in the U.S.
study, our results revealed associations with NHL and multiple SNPs
in the CYP19A1 and ESR1 genes. CYP19A1 encodes for aromatase, a
key enzyme in estrogen production[29] that converts androstenedi-
one and testosterone to estradiol and estrone, respectively. ESR1
encodes estrogen receptor 1 (ERa) that plays an important role in
mediating estrogen action in target tissues. Moreover, ERa signaling
regulates estrogen production by direct modulation of the CYP19A1
promoter[30]. Here we found seven CYP19A1 SNPs associated with
forms of NHL and one, rs1870046, remained associated with FL
(q,0.10). In the replication study, rs1870046 was not successfully
genotyped and no associations were found between SLL/CLL and
rs2899472. Given the extent of associated alleles in the U.S. study
and that only one SNP was investigated in the German study, further
investigation of associated alleles in the CYP19A1 gene is warranted.
The most significant finding in this study was the inverse
association between FL and the C allele in ESR1 rs3020314 that
was corroborated with FL and HL in the German study. Since
estrogen exerts a biphasic dose-dependent effect on the immune
system, this association may be biologically plausible. Notable but
somewhat complex hormonal-driven associations have been
reported between other ESR1 gene variants and breast cancer,
spontaneous abortion, osteoporosis[31], age of menarche[32],
genital abnormalities in men[33] and fertility in men and women.
ESR1 is also expressed by thymocytes and B- and T-cells[34] and
Esr1 knockout mice exhibit compromised thymic[35] and B-cell
development[36], insulin resistance, impaired glucose tolerance
and obesity[37]. Several epidemiological studies have reported
that oral contraceptive use and hormone replacement therapy are
associated with lower lymphoma risk [7,38,39]. Thus, large pooled
gene-environment studies of ESR1 gene variants and measures of
hormone levels or history of hormone use may be useful to further
explore the role of hormones in the pathogenesis of lymphoma.
Lack of additional genetic associations
Few, if any, additional SNP and haplotype associations were
observed in other pathways investigated in this study. For instance,
BIK and EPHX2 were the only genes associated with NHL in the
immunity and xenobiotic metabolism/oxidative stress pathways,
respectively, and no NHL-genetic associations were observed in
the sunlight/vitamin D or folate metabolism pathways. Previous
studies suggest that SNPs in these pathways may influence
lymphoma risk [2]. Our inability to validate these associations
here may be that our study was underpowered to detect significant
associations after adjusting for multiple comparisons; that our
study had incomplete gene coverage; or that other genetic
mechanisms such as copy number variation influenced the results.
Thus, negative results reported here do not dismiss the potential
relevance of these SNPs/pathways in lymphomagenesis, which will
require further study in larger populations.
Perspectives and Future Directions
This study reports novel associations with common variants in
ESR1 and in the vitamin C receptor and matrix metalloproteinase
gene families. Of particular importance is the replication of a
significant association with FL and the ESR1 rs3020314 SNP in a
second independent study of lymphoma, which suggests that
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estrogen bioavailability may be relevant in the pathogenesis of
lymphoma. We also believe that the genetic associations that did
not reach statistical significance in the replication study are
noteworthy, but due to the sample size, may have been
underpowered to detect subtle allelic associations. Given the fact
that we adjusted for multiple comparisons for pathways and did
not adjust for all comparisons with all NHL subtypes, there still is
an increased chance for type 1 errors and it is possible that some of
our results are false positive associations. These findings will need
further validation in larger studies. Owing to the small number of
SNPs analyzed in the replication study, investigation of associated
SNPs identified in the U.S. population will be ongoing. Further
replication, fine mapping and functional studies will also be
needed to determine the causal variants, and pooled data from
consortium studies will be necessary to discern more modest effects
of low penetrance SNPs or for rare alleles. The verification of these
findings could have important implications by providing mecha-
nistic clues in the etiology of lymphoma and in identifying useful
therapeutic targets. Interestingly, most associations were found for
FL and SLL/CLL and few were identified for DLBCL. This may
be due to the heterogeneity of the disease since GC- and post-GC
types of DLBCL exhibit significant molecular diversity at the gene
expression and phenotype levels [45–47] that may require further
stratification to detect underlying DLBCL risk alleles. It may also
be that our hypothesis-driven approach failed to interrogate the
appropriate pathways. To overcome this, we are currently
performing a whole genome scan that will potentially lead to the
identification of novel DLBCL susceptibility alleles.
Materials and Methods
U.S. Study Population
Cases were identified within ,1 month of diagnosis by the
Northern California Cancer Center’s rapid case ascertainment. For
this interim analysis which includes only a subset of the study
participants, eligible patients were diagnosed with incident NHL
from 10/2001–10/2005. All eligible patients were 20–84 years old
and residents of one of six Bay Area counties at the time of diagnosis.
There were 1704 eligible cases interviewed between 10-2001 and
10-2005. An additional 452 cases died prior to initial contact, 272
could not complete an interview in English, 70 had physician
indicated contraindications to contact, 161 could not be located/
moved, 155 were too ill and 360 refused to participate. Pathology
reports and diagnostic materials were obtained from the diagnosing
pathology department and re-reviewed by an expert pathologist to
confirm the diagnosis and to provide a consistent classification of
NHL subtypes using the REAL/WHO[40] lymphoma classifica-
tion. Control participants were identified by random digit dial
supplemented by random sampling of Centers for Medicare &
Medicaid Services lists for those$65 years old. Eligibility criteria for
controls were identical to cases with the exception of NHL
diagnosis. Control participants were frequency matched to cases
by age within five years, sex and county of residence. Among 1939
eligible random-digit-dial controls, 1313 completed in-person
interviews, 85 were too ill and 541 refused to participate. Among
1475 eligible Medicare controls, 768 completed in-person inter-
views, 97 were too ill and 610 refused to participate. Demographic
and risk factor data including HIV status, self-reported race and
ethnicity, and paternal and maternal ancestry, were collected from
all study participants during in-person interviews. No proxy
interviews were conducted. The median time from diagnosis to
venipuncture was 6.5 months. Blood and/or buccal cell specimens
were collected for eligible participants who agreed to biospecimen
collection (87% of cases, 88% of controls).
German Study Population
Detailed information regarding the design of this population-
based case-control study has been published elsewhere[41].
Briefly, the study was carried out from 1999–2002 in six regions
of Germany among 18–80 year-old adults. The study included 710
cases of DLBCL, FL, CLL, multiple myeloma (MM), MALT
lymphoma, T-cell lymphoma and Hodgkin lymphoma (HL) and
710 controls individually matched by sex, age (+/21 year of birth)
and study region. Of these, there were 494 NHL cases and 111
HL cases and matched controls. The median time from diagnosis
to blood collection was 27 days and the response rate for cases and
controls was 87% and 44%, respectively. Analyses for all NHL did
not include MM or HL. For subtype-specific analyses, only FL,
DLBCL, CLL and HL were considered. Incident lymphoma cases
were recruited from hospitals and office-based physicians involved
in diagnosis and treatment of lymphoma in the study regions,
interviewed by trained interviewers and provided blood samples.
Cases were classified according to the WHO system based on
pathology reports and 20% of cases were re-reviewed by a team of
lymphoma pathologists.
The U.C. San Francisco Committee on Human Research, the
U.C. Berkeley Committee for Protection of Human Subjects, and
the Ethics Committee, European Union, approved study proto-
cols. All study participants provided written informed consent
prior to interview and biospecimen collection.
Pathway, Gene and SNP Selection
Eight pathways or groups of genes with common biological
function in a total of 146 genes (Table 1) were chosen to
investigate a priori hypotheses (Table S5) in steroidogenesis,
immune function, cell signaling, sunlight exposure/vitamin D,
xenobiotic metabolism/oxidative stress, energy balance, choles-
terol synthesis/metabolism and diet (folate and vitamin C uptake
and/or metabolism) pathways. 1–15 SNPs in each gene and a total
of 768 SNPs were selected using a minimum minor allele
frequency criterion of $10%, based upon HapMap data release
12 (,October 2004) for CEU Caucasian samples. Additional
coding and regulatory SNPs, especially those with non-synony-
mous amino acid changes, were identified using Ensembl, NCBI,
and SNPper databases [42–47]. For all genes, haplotype tagging
SNPs were selected using Haploview[48] after downloading SNP
genotyping information available for the CEPH population (Utah
residents with ancestry from northern and western Europe) from
the HapMap database (Build 34)[43,49]. SNP validation scores
between 0 and 1 were generated using the Illumina Assay Design
Tool to estimate the likelihood that SNPs would be successfully
genotyped. Through an iterative process, we dropped SNPs with
validation scores ,0.6 and replacement haplotype tagging SNPs
were identified using Haploview until a complete panel of 768
SNPs were chosen. This SNP panel (GS0006402-OPA) was
custom designed by Illumina.
Genotyping
For the U.S. study, genotyping was performed using the
Illumina GoldenGate assay on a BeadStation 500G Genotyping
System. Genotype calls were made using the GenCall version
6.2.0.4 software package (Illumina, Inc., San Diego, CA).
Summary files were generated using the GTS Reports version
5.1.2.0. All SNPs were examined for cluster separation using
Illumina quality scores that were automatically generated by the
software. Poorly performing loci were excluded, designated with a
GenTrain score ,0.4 or a cluster separation score ,0.6. SNPs
were further excluded for scattered or overlapping clusters, for
controls not in Hardy-Weinberg equilibrium, for low frequency
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(,0.05), or for DNA samples with low intensity. Individual DNA
samples were excluded from the study if there was no signal across
SNPs. Genotyping of the German study was performed by
PyrosequencingTM (Biotage, Uppsala, Sweden)[50].
Quality assurance. To validate genotyping results, each 96-
well plate contained 90 randomized study samples, two randomized
replicate study samples placed side-by-side and three laboratory
control DNA samples. DNA also was genotyped from six CEPH
families (Coriell Institute, Camden, NJ). Genotyping of 10 SNPs was
performed for validation purposes using TaqManH genotyping
assays and the ABI Prism 7700 Sequence Detection System (Applied
Biosystems, Foster City, CA).
Coverage estimation. Coverage which indicates the fraction
of common HapMap markers successfully tagged by the set of
genotyped SNPs was estimated using the pairwise tagging method
in Haploview[48], which is based on the Tagger algorithm (www.
broad.mit.edu/mpg/tagger/). SNPs genotyped were forced into a
tag list and neighboring HapMap SNPs were explicitly prohibited
from being chosen as tags. We specified that all HapMap markers
being captured by the set of tags should be correlated at R2$0.8
with at least one marker in the set. HapMap markers with
MAF,0.05 were excluded.
Statistical Analyses
All statistical analyses were restricted to HIV-negative partic-
ipants of white non-Hispanic origin (959 cases, 1,049 controls).
Because self identified ethnicity and ancestry correlates very well
with genetic structure [51], using this information greatly
minimizes the potential effect of underlying population stratifica-
tion on the risk estimates. Hardy-Weinberg equilibria for genotype
frequencies among controls were determined by exact tests using a
Markov-chain method (Genepop v3.4).
SNP analysis. Exact tests were used to generate p-values to
test associations of case-control status and SNP associations. For
each pathway, P-values were corrected for multiple comparisons
(q-values) using the false discovery rate[52]. For all NHL, and for
each subtype tested, the following total number of SNP tests were
performed in each pathway: steroidogenesis, 88; immunity, 75; cell
signaling, 88; sunlight/vitamin D, 53; xenobiotic/metabolism, 40;
energy balance, 155; cholesterol, 62; and diet, 26. Fifty intergenic
SNPs were excluded from the pathway analyses. A threshold of
q,0.10 was used in reporting the most relevant findings in
Tables 2 and 3. ORs and 95% CIs as estimates of the relative risk
were computed adjusted by age and sex from unconditional
logistic regression [53] without taking into account multiple
testing. In genotype analyses, the wild-type category (chosen either
as the most common homozygous genotype or arbitrarily if the
same) was the reference group. The odds ratios from the
unconditional logistic models were adjusted for the frequency-
matched variables age in 5-year groups and sex. Analyses were
performed on all NHL cases and then stratified by DLBCL, FL,
SLL/CLL and ‘‘others.’’ We did not adjust for all multiple
comparisons for all SNPs in all types of lymphoma.
Gene analysis. We tested for multi-way interactions within
sets of SNPs spanning a gene by fitting the genotypes to a linear
regression model and applying a t-test to the case-control
distributions. P-values were generated by permuting cases and
controls, repeating the experiment 10,000 times per gene. Results
were adjusted for multiple hypotheses testing using the FDR for
each functional group/pathway. For ‘‘all NHL’’ and for each
subtype tested, the following total number of gene tests were
performed: steroidogenesis, 22; immunity, 22; cell signaling, 19;
sunlight/vitamin D, 12; xenobiotic/metabolism, 14; energy
balance, 38; cholesterol, 19; and diet, 9.
Haplotype analysis. SNPs were partitioned into blocks of
limited diversity using HAP[54], which uses criteria similar to
previous methods[55]. For each block of limited diversity,
genotypes were phased using PHASE[56]. For each common
haplotype (MAF.5%), a x2-test with one degree of freedom was
performed with counts of haplotype occurrences in cases and
controls. Results were adjusted for multiple hypotheses using the
FDR for each functional group/pathway. For ‘‘all NHL’’ and for
each subtype tested, the following total number of haplotype tests
were performed: steroidogenesis, 44; immunity, 38; cell signaling,
45; sunlight/vitamin D, 31; xenobiotic/metabolism, 19; energy
balance, 91; cholesterol, 36; and diet, 12.
Replication study. Conditional logistic regression analysis
was used to estimate ORs and 95% CIs comparing cases (all NHL
cases combined –which excluded MM and HL- and individual FL,
DLBCL and SLL/CLL subtypes and separate analyses for HL) to
respective controls in association with genotypes, adjusting for
gender, age and study region.
In silico algorithms. The FASTSNP web server[57] was
used to interrogate 11 external web servers including RESCUE-
ESE[13], ESEfinder[58] and PolyPhen[59] to predict the
functionality of SNPs.
Supporting Information
Figure S1 LD plot characterizing haplotype blocks in SCL23A2.
The 7 SLC23A2 SNPs genotyped (rs2298174, rs1629176,
rs1715385, rs6133175, rs1715364, rs1776948 and rs6139587
highlighted in green) captured 35% of genetic variation for the
SLC23A2 locus. Detailed description of LD plots shown in Figures
S1, S2, S3 and S4. R2 values are indicated in percentages within
squares in the LD plot, where red indicates regions of high LD and
white represents regions of low LD. Blocks without numbers
indicate r2 = 1 (100%). At the top, figures display a track with
HapMap genotyped SNPs and genes within the genomic region.
SNPs that have been genotyped in this study are highlighted in
green and marked with lines from the SNP position to the LD
chart. LD blocks were generated using the Confidence Intervals
method included in Haploview4.0 (http://www.broad.mit.edu/
mpg/haploview/index.php), that creates 95% confidence bounds
on D’ considered to be in strong LD where 95% of the
comparisons made are informative. Genotype data was retrieved
from HapMap release 22/phaseII (NCBI B36 assembly), for the
CEPH (Centre d’Etude du Polymorphisme Humain) from Utah
(CEU). Coverages were obtained using the tagging method
included in Haploview as described in the manuscript.
Found at: doi:10.1371/journal.pone.0002816.s001 (59.29MBDOC)
Figure S2 LD plot characterizing haplotype blocks in MMP9.
The 5 MMP9 SNPs genotyped (rs6094237, rs4810482, rs3918241,
rs17576 and rs2274756), highlighted in green, captured 15 out of
19 variations (78%) with r2.0.8. There is, therefore, good
coverage of the MMP9 gene.
Found at: doi:10.1371/journal.pone.0002816.s002 (2.58 MB DOC)
Figure S3 LD plot characterizing haplotype blocks in
CYP19A1. The 14 CYP19A1 SNPs genotyped (rs10046,
rs2289105, rs2899472, rs9944225, rs4775936, rs2008691,
rs4774584, rs7181886, rs936306, rs1004982, rs2470146,
rs2470144, rs1870049 and rs752760 highlighted in green)
captured 66% of genetic variation for CYP19A1.
Found at: doi:10.1371/journal.pone.0002816.s003 (72.13MBDOC)
Figure S4 LD plot characterizing haplotype blocks in ESR1.
The 11 ESR1 SNPs genotyped (rs2881766, rs488133, rs532010,
rs827423, rs1709182, rs1913474, rs3020314, rs722208,
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rs3020411, rs2813545 and rs910416 highlighted in green)
captured 66 out of 262 SNPs at r2.0.8, providing 25% gene
coverage.
Found at: doi:10.1371/journal.pone.0002816.s004 (70.04MBDOC)
Table S1 Odds ratios (OR) and 95% confidence intervals (CI)
for associated SLC23A1 and SLC23A SNPs in the San Francisco
Bay Area NHL study.
Found at: doi:10.1371/journal.pone.0002816.s005 (0.11 MB DOC)
Table S2 Odds ratios (OR) and 95% confidence intervals (CI)
for associated MMP1, 3 and 9 SNPs in the San Francisco Bay
Area NHL study.
Found at: doi:10.1371/journal.pone.0002816.s006 (0.14 MB DOC)
Table S3 Odds ratios (OR) and 95% confidence intervals (CI)
for associated CYP19A1 SNPs in the San Francisco Bay Area
NHL study.
Found at: doi:10.1371/journal.pone.0002816.s007 (0.16 MB DOC)
Table S4 Odds ratios (OR) and 95% confidence intervals (CI)
for associated ESR1 SNPs in the San Francisco Bay Area NHL
study.
Found at: doi:10.1371/journal.pone.0002816.s008 (0.12 MB DOC)
Table S5 A priori hypotheses tested.
Found at: doi:10.1371/journal.pone.0002816.s009 (0.06 MB DOC)
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